These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20178463)

  • 1. Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer?
    Wang X; Li K; Chen H; Wang D; Zhang Y; Bai C
    J Cell Mol Med; 2010 Apr; 14(4):833-9. PubMed ID: 20178463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research progress of HGF/MET signaling pathway in EGFR-TKI resistance 
in non-small cell lung cancer].
    Song S; Bi M
    Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):755-9. PubMed ID: 25342043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].
    Li Y; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):625-34. PubMed ID: 25130970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
    J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
    Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
    J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing.
    Xu KP; Yu FS
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2242-8. PubMed ID: 17460286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 12. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Queiroz de Oliveira PE; Stabile LP
    Mol Pharmacol; 2007 Sep; 72(3):769-79. PubMed ID: 17550984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
    Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
    Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.
    Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS
    Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF-α/EGFR signaling.
    Ito Y; Correll K; Zemans RL; Leslie CC; Murphy RC; Mason RJ
    Am J Physiol Lung Cell Mol Physiol; 2015 Jun; 308(11):L1178-88. PubMed ID: 26033355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment.
    Yao S; Liu X; Feng Y; Li Y; Xiao X; Han Y; Xia S
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to targeted cancer drugs through hepatocyte growth factor signaling.
    Heynen GJ; Fonfara A; Bernards R
    Cell Cycle; 2014; 13(24):3808-17. PubMed ID: 25426675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.